RU2753056C2 - Бициклические гетероарильные производные в качестве стимуляторов cftr - Google Patents

Бициклические гетероарильные производные в качестве стимуляторов cftr Download PDF

Info

Publication number
RU2753056C2
RU2753056C2 RU2019120990A RU2019120990A RU2753056C2 RU 2753056 C2 RU2753056 C2 RU 2753056C2 RU 2019120990 A RU2019120990 A RU 2019120990A RU 2019120990 A RU2019120990 A RU 2019120990A RU 2753056 C2 RU2753056 C2 RU 2753056C2
Authority
RU
Russia
Prior art keywords
pyrrolo
trifluoromethyl
pyrimidin
triazine
amino
Prior art date
Application number
RU2019120990A
Other languages
English (en)
Russian (ru)
Other versions
RU2019120990A3 (enExample
RU2019120990A (ru
Inventor
Джозеф Уолтер СТРОНБЕЧ
Дэвид Кристофер ЛИМБУРГ
Джон Пол МЭТИАС
Этли ТОРАРЕНСЕН
Джеймс Джон МУССО
Рейджиах Алдрин ДЕННИ
Кристоф Вольфганг ЦАПФ
Иван Викторович Ефремов
Original Assignee
Систик Файбросис Фаундейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Систик Файбросис Фаундейшн filed Critical Систик Файбросис Фаундейшн
Publication of RU2019120990A3 publication Critical patent/RU2019120990A3/ru
Publication of RU2019120990A publication Critical patent/RU2019120990A/ru
Application granted granted Critical
Publication of RU2753056C2 publication Critical patent/RU2753056C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2019120990A 2016-12-16 2017-12-14 Бициклические гетероарильные производные в качестве стимуляторов cftr RU2753056C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662435253P 2016-12-16 2016-12-16
US62/435,253 2016-12-16
PCT/US2017/066317 WO2018112149A1 (en) 2016-12-16 2017-12-14 Bycyclic heteroaryl derivatives as cftr potentiators

Publications (3)

Publication Number Publication Date
RU2019120990A3 RU2019120990A3 (enExample) 2021-01-18
RU2019120990A RU2019120990A (ru) 2021-01-18
RU2753056C2 true RU2753056C2 (ru) 2021-08-11

Family

ID=62557188

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019120990A RU2753056C2 (ru) 2016-12-16 2017-12-14 Бициклические гетероарильные производные в качестве стимуляторов cftr

Country Status (10)

Country Link
US (4) US10131670B2 (enExample)
EP (1) EP3554506B1 (enExample)
JP (1) JP7150721B2 (enExample)
CN (1) CN110300589B (enExample)
AU (2) AU2017378324B2 (enExample)
CA (1) CA3046968A1 (enExample)
MX (1) MX391651B (enExample)
RU (1) RU2753056C2 (enExample)
SG (2) SG10201911221RA (enExample)
WO (1) WO2018112149A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS60906B1 (sr) 2014-10-06 2020-11-30 Vertex Pharma Modulatori regulatora transmembranske provodljivosti za cističnu fibrozu
EA201890913A1 (ru) 2015-11-25 2018-11-30 Джилид Аполло, Ллс Пиразоловые соединения в качестве ингибиторов акк и их применение
EA201890949A1 (ru) 2015-11-25 2018-12-28 Джилид Аполло, Ллс СЛОЖНОЭФИРНЫЕ ИНГИБИТОРЫ АЦЕТИЛ-КоА-КАРБОКСИЛАЗЫ И ВАРИАНТЫ ИХ ПРИМЕНЕНИЯ
AU2016359626A1 (en) 2015-11-25 2018-05-17 Gilead Apollo, Llc Fungicidal compositions containing derivatives of 2,4-dioxo-1,4-dihydrothieno(2,3-d)pyrimidine
KR20180082557A (ko) 2015-11-25 2018-07-18 길리어드 아폴로, 엘엘씨 트리아졸 acc 억제제 및 그의 용도
LT3519401T (lt) 2016-09-30 2021-11-25 Vertex Pharmaceuticals Incorporated Cistinės fibrozės transmembraninio laidumo reguliavimo moduliatorius, farmacinės kompozicijos, gydymo būdai ir moduliatoriaus gamybos būdas
MX2021012639A (es) 2016-11-18 2022-10-03 Cystic Fibrosis Found Pirrolopirimidinas como potenciadores de cftr.
PT3551622T (pt) 2016-12-09 2020-11-12 Vertex Pharma Modulador do regulador da condutância transmembrana da fibrose quística, composições farmacêuticas, métodos de tratamento e processo de fabrico do modulador
US11253509B2 (en) 2017-06-08 2022-02-22 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
WO2019018395A1 (en) 2017-07-17 2019-01-24 Vertex Pharmaceuticals Incorporated METHODS OF TREATING CYSTIC FIBROSIS
TWI799435B (zh) 2017-08-02 2023-04-21 美商維泰克斯製藥公司 製備化合物之製程
US10654829B2 (en) 2017-10-19 2020-05-19 Vertex Pharmaceuticals Incorporated Crystalline forms and compositions of CFTR modulators
CA3085006A1 (en) 2017-12-08 2019-06-13 Vertex Pharmaceuticals Incorporated Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
CA3088577A1 (en) 2018-02-15 2019-08-22 Vertex Pharmaceuticals Incorporated Macrocycles as modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions thereof, their use in the treatment of cycstic fibrosis, and process for making them
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
TWI848092B (zh) 2019-04-03 2024-07-11 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白調節劑
EP3980121A1 (en) * 2019-06-10 2022-04-13 Novartis AG Pyridine and pyrazine derivative for the treatment of cf, copd, and bronchiectasis
CN114007616A (zh) 2019-07-15 2022-02-01 诺华股份有限公司 (s)-3-氨基-6-甲氧基-n-(3,3,3-三氟-2-羟基-2-甲基丙基)-5-(三氟甲基)吡啶甲酰胺的配制品
TWI867024B (zh) 2019-08-14 2024-12-21 美商維泰克斯製藥公司 囊腫纖維化跨膜傳導調節蛋白之調節劑
TWI899097B (zh) 2019-08-14 2025-10-01 美商維泰克斯製藥公司 製備cftr調節劑之方法
US11873300B2 (en) 2019-08-14 2024-01-16 Vertex Pharmaceuticals Incorporated Crystalline forms of CFTR modulators
JP7784041B2 (ja) * 2020-04-07 2025-12-11 アイテオ ベルギウム エスエー がんの治療のためのent阻害剤としての大環状ジアミン誘導体、及びそれとアデノシン受容体拮抗薬との組合せ
WO2022036060A1 (en) 2020-08-13 2022-02-17 Vertex Pharmaceuticals Incorporated Crystalline forms of cftr modulators
IL300405A (en) 2020-08-20 2023-04-01 Univ Leland Stanford Junior Methods for treating respiratory diseases characterized by excessive secretion of mucus
US12612416B2 (en) 2020-10-07 2026-04-28 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
IL303519A (en) 2020-12-10 2023-08-01 Vertex Pharma Cystic fibrosis treatment methods
CN112876524B (zh) * 2021-01-26 2022-10-28 上海法默生物科技有限公司 一种瑞德西韦中间体的制备方法

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005007085A2 (en) * 2003-06-20 2005-01-27 The Regents Of The University Of California Pyrazolo pyrimidine derivatives and methods of use thereof
WO2007079164A2 (en) * 2005-12-29 2007-07-12 Abbott Laboratories Protein kinase inhibitors
RU2331642C2 (ru) * 2002-07-19 2008-08-20 Бристол-Маерс Сквибб Компани Новые ингибиторы киназ
EA201070572A1 (ru) * 2007-11-07 2010-12-30 Фолдркс Фармасьютикалз, Инк. Модуляция транспорта белков
EA019961B1 (ru) * 2006-04-04 2014-07-30 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Антагонисты киназы
EA201400707A1 (ru) * 2011-12-15 2014-11-28 Байер Фарма Акциенгезельшафт Дизамещенные бензотиенил-пирролотриазины и их применение в качестве ингибиторов киназы рфрф
EA025177B1 (ru) * 2010-02-05 2016-11-30 Адверио Фарма Гмбх СТИМУЛЯТОР sGC ИЛИ АКТИВАТОР sGC, ПРИМЕНЯЕМЫЙ ДЛЯ ЛЕЧЕНИЯ КИСТОЗНОГО ФИБРОЗА ОТДЕЛЬНО ИЛИ В КОМБИНАЦИИ С ИНГИБИТОРОМ PDE5

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10135815A1 (de) * 2001-07-23 2003-02-06 Bayer Ag Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen
WO2004100868A2 (en) * 2003-04-23 2004-11-25 Abbott Laboratories Method of treating transplant rejection
KR101461680B1 (ko) 2005-12-02 2014-11-19 바이엘 헬스케어 엘엘씨 과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체
CA2915418C (en) * 2013-07-02 2022-05-03 Rhizen Pharmaceuticals Sa Novel selective pi3k delta and/or gamma protein kinase inhibitors
MX2021012639A (es) 2016-11-18 2022-10-03 Cystic Fibrosis Found Pirrolopirimidinas como potenciadores de cftr.

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2331642C2 (ru) * 2002-07-19 2008-08-20 Бристол-Маерс Сквибб Компани Новые ингибиторы киназ
WO2005007085A2 (en) * 2003-06-20 2005-01-27 The Regents Of The University Of California Pyrazolo pyrimidine derivatives and methods of use thereof
WO2007079164A2 (en) * 2005-12-29 2007-07-12 Abbott Laboratories Protein kinase inhibitors
EA019961B1 (ru) * 2006-04-04 2014-07-30 Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния Антагонисты киназы
EA201070572A1 (ru) * 2007-11-07 2010-12-30 Фолдркс Фармасьютикалз, Инк. Модуляция транспорта белков
EA025177B1 (ru) * 2010-02-05 2016-11-30 Адверио Фарма Гмбх СТИМУЛЯТОР sGC ИЛИ АКТИВАТОР sGC, ПРИМЕНЯЕМЫЙ ДЛЯ ЛЕЧЕНИЯ КИСТОЗНОГО ФИБРОЗА ОТДЕЛЬНО ИЛИ В КОМБИНАЦИИ С ИНГИБИТОРОМ PDE5
EA201400707A1 (ru) * 2011-12-15 2014-11-28 Байер Фарма Акциенгезельшафт Дизамещенные бензотиенил-пирролотриазины и их применение в качестве ингибиторов киназы рфрф

Also Published As

Publication number Publication date
JP7150721B2 (ja) 2022-10-11
EP3554506B1 (en) 2021-04-28
MX391651B (es) 2025-03-21
US10131670B2 (en) 2018-11-20
CA3046968A1 (en) 2018-06-21
RU2019120990A3 (enExample) 2021-01-18
US20190330219A1 (en) 2019-10-31
SG10201911076QA (en) 2020-01-30
US10377762B2 (en) 2019-08-13
US20180170938A1 (en) 2018-06-21
MX2019007135A (es) 2019-11-18
AU2017378324B2 (en) 2021-09-02
CN110300589A (zh) 2019-10-01
CN110300589B (zh) 2023-03-10
AU2021277702B2 (en) 2023-11-30
JP2020502103A (ja) 2020-01-23
RU2019120990A (ru) 2021-01-18
AU2021277702A1 (en) 2021-12-23
AU2017378324A1 (en) 2019-06-27
US20190016728A1 (en) 2019-01-17
EP3554506A4 (en) 2020-06-10
EP3554506A1 (en) 2019-10-23
US10208053B2 (en) 2019-02-19
SG10201911221RA (en) 2020-02-27
BR112019012335A2 (pt) 2020-03-03
US10766904B2 (en) 2020-09-08
WO2018112149A1 (en) 2018-06-21
US20190016727A1 (en) 2019-01-17

Similar Documents

Publication Publication Date Title
US10766904B2 (en) Bicyclic heteroaryl derivatives as CFTR potentiators
US12612409B2 (en) Pyrrolopyrimidines as CFTR potentiators
HK40015891B (en) Bycyclic heteroaryl derivatives as cftr potentiators
HK40015891A (en) Bycyclic heteroaryl derivatives as cftr potentiators
BR122024011694A2 (pt) Compostos derivados de heteroarila bicíclica como potenciadores de cftr, composição farmacêutica que compreende os mesmos e uso dos ditos compostos para tratar fibrose cística, asma, bronquiectasia, doença pulmonar obstrutiva crônica, constipação, diabetes mellitus, doença do olho seco, pancreatite, rinossinusite ou síndrome de sjogren
BR112019012335B1 (pt) Compostos derivados de heteroarila bicíclica como potenciadores de cftr, composição farmacêutica que compreende os mesmos e uso dos ditos compostos para tratar fibrose cística, asma, bronquiectasia, doença pulmonar obstrutiva crônica, constipação, diabetes mellitus, doença do olho seco, pancreatite, rinossinusite ou síndrome de sjogren
BR122024011694B1 (pt) Compostos derivados de heteroarila bicíclica como potenciadores de cftr, composição farmacêutica que compreende os mesmos e uso dos ditos compostos para tratar fibrose cística, asma, bronquiectasia, doença pulmonar obstrutiva crônica, constipação, diabetes mellitus, doença do olho seco, pancreatite, rinossinusite ou síndrome de sjogren
HK40014108A (en) Pyrrolopyrimidines as cftr potentiators
HK40014108B (en) Pyrrolopyrimidines as cftr potentiators
BR122022008825B1 (pt) Compostos pirrolopirimidinas potenciadores de cftr, composição farmacêutica que compreende os mesmos e usos terapêuticos dos ditos compostos e composição
BR112019010167B1 (pt) Compostos pirrolopirimidinas potenciadores de cftr

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant